Guardant Health, Inc. (GH) Q1 FY26 Earnings Call

Strong broad-based growth drove a 2026 revenue-guide raise, but commercial investment and reimbursement execution remain key variables.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length62 minutes
EPS$-0.85
EPS consensus$-0.71
Revenue$301.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All GH earnings ยท Back to GH overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.